Stock PUR PURE BIOLOGICS S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Pure Biologics S.A. Stock

Equities

PUR

PLPRBLG00010

Biotechnology & Medical Research

Market Closed - Warsaw S.E.
Other stock markets
 11:55:42 2024-04-26 EDT 		5-day change 1st Jan Change
7.81 PLN +0.64% Intraday chart for Pure Biologics S.A. -3.46% -38.21%
2023 Pure Biologics S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
2023 Pure Biologics S.A. Reports Earnings Results for the Half Year Ended June 30, 2023 CI

Financials

Sales 2021 254K 63.13K 86.24K Sales 2022 662K 165K 225K Capitalization 51.84M 12.88M 17.6M
Net income 2021 -11M -2.73M -3.74M Net income 2022 -25M -6.21M -8.49M EV / Sales 2021 573 x
Net cash position 2021 29.82M 7.41M 10.12M Net cash position 2022 4.32M 1.07M 1.47M EV / Sales 2022 71.8 x
P/E ratio 2021
-14.7 x
P/E ratio 2022
-2 x
Employees 96
Yield 2021 *
-
Yield 2022
-
Free-Float 85.51%
More Fundamentals * Assessed data

Chart Pure Biologics S.A.

Dynamic Chart

Latest news about Pure Biologics S.A.

Pure Biologics S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Pure Biologics S.A. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Pure Biologics Spólka Akcyjna Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Pure Biologics Spólka Akcyjna Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Presage Announces Collaboration with Pure Biologics to Investigate Oncology Agents in Early Development with CIVO® Technology CI
Dom Maklerski Navigator S.A. and IPOPEMA Securities S.A. agreed to acquire an unknown minority stake in Pure Biologics Spólka Akcyjna. CI
Pure Biologics Spólka Akcyjna Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Pure Biologics Spólka Akcyjna Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Pure Biologics Spólka Akcyjna Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Pure Biologics Spólka Akcyjna Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Pure Biologics Sp?lka Akcyjna Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Pure Biologics Spólka Akcyjna Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Pure Biologics Spólka Akcyjna announced that it has received €6.7 million in funding from National Centre for Research and Development CI
Pure Biologics Spólka Akcyjna announced that it has received PLN 10.1 million in funding CI
More news

Quotes and Performance

1 day+0.64%
1 week-3.46%
Current month-3.46%
1 month-3.46%
3 months-30.76%
6 months-36.40%
Current year-38.21%
More quotes

Highs and lows

1 week
7.76
Extreme 7.76
8.02
1 month
7.72
Extreme 7.72
8.49
Current year
6.95
Extreme 6.95
16.98
1 year
5.01
Extreme 5.01
21.90
3 years
5.01
Extreme 5.01
118.60
5 years
5.01
Extreme 5.01
152.00
10 years
5.01
Extreme 5.01
152.00
More quotes

Managers and Directors - Pure Biologics S.A.

Managers TitleAgeSince
Maciej Piotr Mazurek FOU
 Founder - 09-12-31
Filip Jan Jelen CEO
 Chief Executive Officer 47 09-12-31
Romuald Harwas DFI
 Director of Finance/CFO 52 19-12-15
Members of the board TitleAgeSince
Tadeusz Wesolowski BRD
 Director/Board Member 72 19-05-06
Andrzej Jan Trznadel FOU
 Founder 62 09-12-31
Pawel Marcin Wisniewski BRD
 Director/Board Member 44 23-05-25
More insiders

Quotes

Date Price Change Volume
24-04-26 7.81 +0.64% 5,117
24-04-25 7.76 -0.51% 3,816
24-04-24 7.8 -1.89% 2,812
24-04-23 7.95 0.00% 5,352
24-04-22 7.95 -1.73% 4,527

Delayed Quote Warsaw S.E., April 26, 2024 at 11:55 am

More quotes

Company Profile

Pure Biologics SA is a manufacturer of biological products. The Company was founded in August 2010 and is located in Wroclaw, Poland.
Sector
Biotechnology & Medical Research
More about the company

Income Statement Evolution

More financial data

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
PURE BIOLOGICS S.A. Stock Pure Biologics S.A.
-38.21% 6.42M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. PUR Stock